BRD4 Inhibitor-20
CAS No. 2490311-14-1
BRD4 Inhibitor-20( —— )
Catalog No. M35542 CAS No. 2490311-14-1
BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 58 | Get Quote |
|
| 5MG | 88 | Get Quote |
|
| 10MG | 145 | Get Quote |
|
| 25MG | 273 | Get Quote |
|
| 50MG | 412 | Get Quote |
|
| 100MG | 567 | Get Quote |
|
| 500MG | 1116 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBRD4 Inhibitor-20
-
NoteResearch use only, not for human use.
-
Brief DescriptionBRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity, demonstrating antiproliferative effects in cancer cell lines and used in studies of various cancers, including colon cancer.
-
DescriptionBRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC50 values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer.
-
In VitroBRD4 Inhibitor-20 (compound 12j) exhibits excellent BRD4 inhibitory activities (BD1, IC50=19 nM; BD2, IC50=28 nM) and inhibitory activities against BRD2 (BD1, IC50=24 nM; BD2, IC50=18 nM).BRD4 Inhibitor-20 (0.5, 2.5, 5.0 μM; 24 h) reduces the expression of c-Myc.BRD4 Inhibitor-20 (72 h) has anti-proliferation potency with IC50 values of 4.75 μM, 1.35 μM and 44.07 μM in HT-29, HL-60 and WI-38 cells, respectively.BRD4 Inhibitor-20 (2.5, 5.0, 10.0 μM; 24 h) can arrest the cell-cycle progression of HT-29 cells into the G1 phaseWestern Blot Analysis Cell Line:HT-29 cells Concentration:0.5, 2.5, 5.0 μM Incubation Time:24 h Result: Displayed profound inhibitory effects on c-Myc protein expression.Cell Proliferation Assay Cell Line:HT-29, HL-60 and WI-38 cells Concentration:Incubation Time:72 h Result:Possessed strong anti-proliferative activity and weak toxicity.Cell Cycle Analysis Cell Line:HT-29 cell lines Concentration:2.5, 5.0, 10.0 μM Incubation Time:24 h Result:Arrested the cell-cycle progression of the cell line into the G1 phases and the percentage of cells in G1 phase after treatment under concentrations of 2.5, 5.0 and 10.0 μM were 85.98%, 86.49% and 86.05%, respectively.
-
In VivoBRD4 Inhibitor-20 (compound 12j) (i.v., 5 mg/kg; p.o, 15mg/kg) exhibits favorable oral pharmacokinetic propertie.
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2490311-14-1
-
Formula Weight358.41
-
Molecular FormulaC18H18N2O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (348.76 mM; Ultrasonic (<60°C)
-
SMILESC(C)(C)=C1C=2C(NC1=O)=CC=C(NS(=O)(=O)C3=C(OC)C=CC=C3)C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yu Xu, et al. Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors. Eur J Med Chem. 2020 Dec 15;208:112780.?
molnova catalog
related products
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
-
dCBP-1
dCBP-1 is a chemical degrader of p300/CBP. dCBP-1 hijacks the E3 ubiquitin ligase CRBN for selective degradation of p300/CBP. Degradation of p300/CBP by dCBP-1 leads to effective multiple myeloma cell killing.
-
BET bromodomain inhi...
It is a BET bromodomain inhibitor.
Cart
sales@molnova.com